Disc Medicine, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Disc Medicine, Inc. (IRON) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of 4.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2024-03-21
- Disc Medicine, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 4.00%, a 14.29% increase from fiscal 2022.
- Disc Medicine, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 3.50%, a 169.23% increase from fiscal 2021.
- Disc Medicine, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 1.30%, a 56.67% decline from fiscal 2020.
- Disc Medicine, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2020 was 3.00%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2023-12-31 | 4.00% 10-K · filed 2024-03-21 | |
| 2022-12-31 | 3.50% 10-K · filed 2024-03-21 | |
| 2021-12-31 | 1.30% 10-K · filed 2023-03-31 | 2.90% 10-K · filed 2022-03-10 |
| 2020-12-31 | 3.00% 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |